The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The use of belantamab mafodotin in triplet combinations for multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses recent findings on triplet combinations containing belantamab mafodotin for the treatment of multiple myeloma. In the DREAMM-8 (NCT04484623) study, the belantamab mafodotin combination showed superiority over the control arm, potentially offering a new standard of care for lenalidomide-refractory patients. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Recently there has been a publication, a presentation on two important belantamab mafodotin containing combinations. One with bortezomib and dexamethasone, and in this particular combination, this particular combination was compared to daratumumab, bortezomib, and dexamethasone, and it showed that the belantamab mafodotin arm was superior to the control arm as far as response is concerned, but also progression-free survival (PFS)...
Recently there has been a publication, a presentation on two important belantamab mafodotin containing combinations. One with bortezomib and dexamethasone, and in this particular combination, this particular combination was compared to daratumumab, bortezomib, and dexamethasone, and it showed that the belantamab mafodotin arm was superior to the control arm as far as response is concerned, but also progression-free survival (PFS). In the DREAMM-8 study, the investigational alarm consisted of belantamab mafodotin with pomalidomide and dexamethasone and the control arm was PVd. In this particular trial not only lenalidomide-refractory patients were included, but also patients who have been exposed and several of them were refractory to anti-CD38, were included as well. This study showed that the combination of belantamab mafodotin with pomalidomide and dexamethasone was superior and may represent a new standard of care for patients who progress on lenalidomide and daratumumab.
Read more...
